Leading pharmaceuticals sector company Glenmark Pharma share price today plunged 1.01% to Rs 1381.20 per share on Bombay Stock Exchange (BSE). The company today informed about its upcoming meeting of Board of Directors scheduled to be held on May 23, 2025 to consider financial results and dividend, if any. The stock offered shareholders returns of 34.80% in last 1-year but plunged 14.43% year-to-date. Meanwhile, the company’s market cap stood at Rs 38,977.58 crore. Its return on equity (ROE) stood at 25.38%. It is worth mentioning that FII/FPI holding plunged from 23.51% to 23.15% for March 2025 quarter. Check key details below:
Glenmark Pharma To Consider Results, Dividend On May 23, 2025
According to the exchange filing of the company dated May 12, 2025, “A meeting of the Board of Directors will be held on Friday, May 23, 2025, inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2025 and to consider and recommend dividend, if any, on Equity shares for the year ended March 31, 2025.”
Glenmark Pharma Shares Performance
The 52-week high price of Glenmark Pharmaceuticals shares on BSE stood at Rs 1830.05 per share (as on 15/10/2024) and 52-week low price is Rs 985.60 per share (as on 16/05/2024), respectively. Glenmark Pharmaceuticals shares witnessed correction of over 12% in last 6-months, surged 125.43% in last 2-years, and rallied 254% in last 3-years. The stock gained 315.77% in last 5-years.
Glenmark Pharmaceuticals Dividend History
The pharma company recommended 24 dividends since 2001. In last 1-year period, it declared a dividend of Rs 2.50 per share. It offers a dividend yield of 0.18%.
Glenmark Pharmaceuticals Bonus Share History
Glenmark recommended bonus share once since 2005. Its last bonus issue was declared in the proportion of 1:1 with ex-bonus date set as March 4, 2005.
Glenmark Pharmaceuticals Stock Split History
It has split the face value of its share twice since 2003. It last split/sub-divided the face value of its shares from Rs 2 to Re 1 in 2007 and set ex-split on September 10, 2007.
Why Pharma Stocks Slipped Today?
Several pharma stocks witnessed steep fall on Monday, May 12, 2025 after US President Donald Trump shared his latest post on his social media network “Truth Social”. The President said that he is planning to sign an executive order on Monday at 9 AM Washington time that will reduce costs of prescription and pharmaceuticals drugs roughly 30% to 80% with immediate effect. Trump state he plans to institute a most favoured nations policy, whereby the United States will pay the same price as the Nation that pays the lowest price anywhere in the World.” Healthcare costs in the US “will be reduced by numbers never even thought of before.”
Should You Buy Glenmark Pharma As Shares Plunged 24.5% From 52-Week High?
The stock witnessed decline of 24.5% from 52-week high price of Rs 1830.05 per share at last trading price of Rs 1381.20 per share. Meanwhile, the stock is on buy call with target price of Rs 1691 per share. Out of a total of 12 analysts tracking the stock, 9 have recommended buy call, 2 suggested hold call, and remaining one suggested sell call.
About
Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.
Disclaimer: The stock has been picked from the consensus brokerage report of Trendlyne. Moneydaily.in, the author, and the respective brokerage house will not be held accountable for any losses caused as a result of decisions based on the article. Moneydaily.in advises readers to do their own research or consult a SEBI registered investment advisor before making any investment decisions.
Leave a Reply